Studying relmacabtagene autoleucel cell therapy in adults with B-cell lymphoma
Observes relmacabtagene autoleucel, a cell therapy, in adults with B-cell lymphoma.
Plain-language title generated from the registry record
Registry title: Relmacabtagene Autoleucel in Hematologic Malignancies
Key facts
- Where
- Beijing, ChinaSee the 2 sites
Where in China
- Beijing Cancer HospitalBeijing, ChinaNo longer taking part
- Peking University International HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Ming Ju Biotechnology Co., Ltd.
- Trial code
- NCT06142188
- Record updated
- 21 November 2023
- Original description
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-worldRead full original descriptionShow less
A Real-world Study for the Treatment of Hematologic Malignancies With Relmacabtagene Autoleucel
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
Inclusion: Signed informed consent; Patients who have been treated with Relma-cel, including those who have received off-label products; If previously enrolled in another clinical study, they must have completed follow-up in the previous study, or have withdrawn or lost follow-up in the previous study.
Exclusion: 1.Patients who have been treated with Relma-cel and then have been treated with other CAR-T products.